[1] Singal A G, Kanwal F, Llovet J M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy[J]. Nat Rev Clin Oncol, 2023, 20(12): 864-884. [2] 陆明江. 阿替利珠单抗与索拉非尼在TACE抵抗中晚期肝癌患者治疗中的有效性及安全性对比[J]. 延边大学医学学报, 2025, 48(12): 81-83. [3] 刘志英, 周智航, 何松. 血液代谢标志物在原发性肝癌治疗反应及预后预测中的应用[J]. 临床肝胆病杂志, 2023, 39(10): 2470-2475. [4] Zeng H, Zhang D, Yang Z, et al. Cholesterol and C-reactive protein prognostic score predicted prognosis of immune checkpoint inhibitors based interventional therapies for intermediate-to-advanced hepatocellular carcinoma patients[J]. Int Immunopharmacol, 2023, 115: 109651. [5] Su T H, Huang S C, Chen C L, et al. Pre-operative gamma-glutamyl transferase levels predict outcomes in hepatitis B-related hepatocellular carcinoma after curative resection[J]. J Formos Med Assoc, 2023, 122(10): 1008-1017. [6] 王瑶, 徐璐, 王云杰, 等. 免疫细胞与肝细胞性肝癌的因果关系:孟德尔随机化研究[J]. 临床检验杂志, 2025, 43(5): 362-368. [7] 李凌巍, 秦俊杰, 贾云龙, 等. 孟德尔随机化在肝癌研究中的应用[J]. 临床肝胆病杂志, 2024, 40(2): 391-396. [8] Xu M, Zheng J, Hou T, et al. SGLT2 inhibition, choline metabolites, and cardiometabolic diseases: a mediation Mendelian randomization study[J]. Diabetes Care, 2022, 45(11): 2718-2728. [9] Sinnott-Armstrong N, Tanigawa Y, Amar D, et al. Genetics of 35 blood and urine biomarkers in the UK Biobank[J]. Nat Genet, 2021, 53(2): 185-194. [10] Palmer T M, Lawlor D A, Harbord R M, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors[J]. Stat Methods Med Res, 2012, 21(3): 223-242. [11] Qin Y, Havulinna A S, Liu Y, et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort[J]. Nat Genet, 2022, 54(2): 134-142. [12] Zhang B, He W, Pei Z, et al. Plasma proteins, circulating metabolites mediate causal inference studies on the effect of gut bacteria on the risk of osteoporosis development[J]. Ageing Res Rev, 2024, 101: 102479. [13] Kurki M I, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population[J]. Nature, 2023, 613(7944): 508-518. [14] Zhao J, Ming J, Hu X, et al. Bayesian weighted Mendelian randomization for causal inference based on summary statistics[J]. Bioinformatics, 2020, 36(5): 1501-1508. [15] Yang C, Liang Z, Zhao L, et al. Prediction of microvascular invasion in hepatocellular carcinoma using a preoperative serum C-reactive protein-based nomogram[J]. Sci Rep, 2025, 15(1): 522. [16] Naqash A R, Mccallen J D, Mi E, et al. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer[J]. J Immunother Cancer, 2023, 11(10): e007310. [17] Feng Z, Cao K, Sun H, et al. SEH1L silencing induces ferroptosis and suppresses hepatocellular carcinoma progression via ATF3/HMOX1/GPX4 axis[J]. Apoptosis, 2024, 29(9-10): 1723-1737. [18] Huang C F, Jang T Y, Jun D W, et al. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients[J]. Liver Int, 2022, 42(1): 59-68. [19] Yang Z, Shao X, Wu Y, et al. Decoding potassium homeostasis in cancer metastasis and drug resistance: insights from a highly selective DNAzyme-based intracellular K+ sensor[J]. J Am Chem Soc, 2025, 147(21): 18074-18087. [20] Chen S, Cui W, Chi Z, et al. Tumor-associated macrophages are shaped by intratumoral high potassium via Kir2.1[J]. Cell Metab, 2022, 34(11): 1843-1859.e11. [21] He Y, Lin Y, He F, et al. Role for calcium-activated potassium channels (BK) in migration control of human hepatocellular carcinoma cells[J]. J Cell Mol Med, 2021, 25(20): 9685-9696. [22] Chen H K, Lan Q W, Li Y J, et al. Association between dietary potassium intake and nonalcoholic fatty liver disease and advanced hepatic fibrosis in U.S. adults[J]. Int J Endocrinol, 2024, 2024: 5588104. [23] Yan F, Zhang Q, Shi K, et al. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response[J]. Front Cell Infect Microbiol, 2023, 13: 1152987. [24] Wang X, Fang Y, Liang W, et al. Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice[J]. Nat Microbiol, 2025, 10(1): 169-184. [25] Lau H C, Zhang X, Ji F, et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid[J]. EBioMedicine, 2024, 100: 104952. |